Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial - 10/08/11
, Amy S. Paller, MD b, Adelaide A. Hebert, MD c, Kara Creamer, MS d, Haoling H. Weng, MD d, Angelika Jahreis, MD, PhD d, Denise Globe, PhD d, Vaishali Patel, PharmD, MS d, Seth J. Orlow, MD, PhD e
Reprint requests: Richard G. Langley, MD, Division of Dermatology, Dalhousie University, QE2 Health Science Center, 4195 Dixon Bldg, 5820 University, Halifax, NS, Canada, B3H1V8.Abstract |
Background |
Psoriasis adversely affects health-related quality of life (HRQoL) in adults; however, little information exists about its impact on children and adolescents.
Objective |
The effect of etanercept therapy on HRQoL compared with placebo was evaluated in children and adolescents with moderate to severe plaque psoriasis.
Methods |
HRQoL data were collected from patients 4 to 17 years of age in a randomized, double-blind, placebo-controlled, North American, phase III study of etanercept. Instruments for assessing HRQoL included the Children’s Dermatology Life Quality Index (CDLQI), Pediatric Quality of Life Inventory (PedsQL), Stein Impact on Family Scale, and Harter Self-Perception Profile for Children.
Results |
Baseline CDLQI and PedsQL scores revealed reduced HRQoL in patients with psoriasis relative to comparative populations. Patients treated with etanercept demonstrated significantly higher mean percentage improvement in total CDLQI scores from baseline to week 12 compared with those treated with placebo (52.3% etanercept vs 17.5% placebo [P = .0001]). At week 12, patients who achieved 75% improvement in their Psoriasis Area and Severity Index score had higher percentage improvements from baseline in total CDLQI scores than those who did not have 75% improvement in Psoriasis Area and Severity Index score.
Limitations |
The PedsQL, Stein scale, and Harter profile demonstrated limited improvement in patients’ HRQoL, suggesting that these scales may not be sensitive to issues that are relevant to children with psoriasis and their families.
Conclusion |
Etanercept therapy had a clinically and statistically meaningful impact on disease-specific quality of life (CDLQI) and a clinically meaningful impact on general quality of life (PedsQL) in children and adolescents with moderate to severe plaque psoriasis.
Le texte complet de cet article est disponible en PDF.Key words : Children’s Dermatology Life Quality Index, Harter Self-Perception Profile for Children, health-related quality of life, pediatric plaque psoriasis, Pediatric Quality of Life Inventory, Stein Impact on Family Scale
Abbreviations used : CDLQI, DLQI, HRQoL, MID, PASI, PASI 75, PedsQL
Plan
| Drs Jahreis and Patel are former employees of Amgen Inc; they are currently employed by Genentech and Allergan, respectively. |
|
| This analysis was designed by Amgen Inc and funded by Immunex Corp, a wholly owned subsidiary of Amgen Inc, and by Wyeth, which was acquired by Pfizer Inc in October 2009. Financial support for the preparation of the manuscript was provided by Amgen Inc. |
|
| Disclosure: Dr Langley has received investigator grants from Amgen, Schering, Abbott, Centocor, LEO Pharma, Novartis, Celgene, Pfizer, NanoBio, Serono, Bristol-Myers Squibb, and Isotechnika, and has received honoraria from serving on the scientific advisory boards for Amgen, Schering, and Abbott. Dr Paller has served as an investigator for Amgen without compensation, but has received honoraria from Amgen and Centocor/Johnson & Johnson as a consultant. Dr Hebert has received compensation from Amgen as a consultant and has served as a researcher for Amgen without compensation. Dr Orlow has been an investigator for Amgen without compensation, but has received honoraria from Amgen and Centocor/Johnson & Johnson as a consultant, and his department has been the recipient of an unrestricted educational grant from Amgen. Ms Creamer and Drs Weng and Globe are Amgen employees and have Amgen stock and stock options. Drs Jahreis and Patel were Amgen employees at the time this manuscript was drafted and held Amgen stock and stock options. |
Vol 64 - N° 1
P. 64-70 - janvier 2011 Retour au numéro
Article précédent
- The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome
- Ming Yang Bi, Jonathan L. Curry, Angela M. Christiano, Maria K. Hordinsky, David A. Norris, Vera H. Price, Madeleine Duvic
- Psoriasis and pregnancy outcomes: A nationwide population-based study
- Ya-Wen Yang, Chin-Shyan Chen, Yi-Hua Chen, Herng-Ching Lin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?